Science Explorer Back to mapMap
Discussion
Topic · Oncology

HER2/EGFR in Cancer Research

HER2/EGFR in Cancer Research is a research topic within Oncology. Science Explorer counts 34k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the use of HER2-targeted therapies, such as trastuzumab and pertuzumab, in the treatment of HER2-positive breast cancer. It explores the mechanisms of action, resistance, and combination therapies involving chemotherapy and monoclonal antibodies. The cluster also delves into the role of EGFR, neuregulin 1, and ADAM metalloproteinases in HER2 signaling and breast cancer progression.

  • HER2
  • breast cancer
  • trastuzumab
  • EGFR
  • monoclonal antibody
  • chemotherapy
  • metastatic
  • receptor tyrosine kinases
  • neuregulin 1
  • ADAM metalloproteinases
Research works
34k
fractional, since 1950
In the world top 10%
3.5k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+29%
the tick is no change
Largest producer
United States
33% of the 10 largest, 2022-now
HER2/EGFR in Cancer Research

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead HER2/EGFR in Cancer Research research?

By volume, the United States and China publish the most (2k and 1.7k works in 2022-now).

By volume, 2022-now

  1. 1 United States 2k works
  2. 2 China 1.7k works
  3. 3 Japan 406 works
  4. 4 India 331 works
  5. 5 Italy 298 works
  6. 6 Germany 286 works
  7. 7 United Kingdom 252 works
  8. 8 South Korea 228 works
  9. 9 Spain 226 works
  10. 10 France 215 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 33.1%China: 29.1%Japan: 6.8%India: 5.6%6 others listed: 25.4%33%largest
United States1,963 · 33.1%China1,729 · 29.1%Japan406 · 6.8%India331 · 5.6%6 others listed1,506 · 25.4%

Shares of the rows listed above, not of the whole node.

Which institutions lead HER2/EGFR in Cancer Research research?

By volume in 2022-now, Harvard University publishes the most HER2/EGFR in Cancer Research research, followed by The University of Texas MD Anderson Cancer Center and Sun Yat-sen University.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 110 works
  2. 2 The University of Texas MD Anderson Cancer CenterUnited States 78 works
  3. 3 Sun Yat-sen UniversityChina 77 works
  4. 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 60 works
  5. 5 Peking UniversityChina 54 works
  6. 6 Memorial Sloan Kettering Cancer CenterUnited States 51 works
  7. 7 University of North Carolina at Chapel HillUnited States 45 works
  8. 8 AstraZeneca (United Kingdom)United Kingdom 44 works
  9. 9 Sichuan UniversityChina 42 works
  10. 10 Nanjing Medical UniversityChina 40 works

Who are the leading researchers in HER2/EGFR in Cancer Research?

The most-cited researchers publishing on HER2/EGFR in Cancer Research include Eric S. Lander, Stacey L. Gabriel and Guido Kroemer.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 Stacey L. Gabriel United States 402k citations
  3. 3 Guido Kroemer France 386k citations
  4. 4 Bert Vogelstein United States 373k citations
  5. 5 Gad A. Getz United States 364k citations
  6. 6 Elaine R. Mardis United States 346k citations
  7. 7 Hermann Brenner Germany 343k citations
  8. 8 Jun Wang China 340k citations
  9. 9 Matthias Mann Germany 308k citations
  10. 10 Róbert Langer United States 303k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in HER2/EGFR in Cancer Research?

The most cited paper in HER2/EGFR in Cancer Research is "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene" (Dennis J. Slamon, Gary M. Clark, Steven Wong et al., 1987), with 11,844 citations. Next come "Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2" (11,628) and "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib" (11,595).

Most cited papers
#PaperReleasedCitations
1 Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science 9 Jan 1987 11,844
2 Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian R Leyland-Jones, Steven Shak et al. · New England Journal of Medicine Open access 15 Mar 2001 11,628
3 Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas James Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine 19 May 2004 11,595
4 EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi Antero Janne, Jeffrey C. Lee et al. · Science 3 May 2004 9,471
5 Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon, Joseph Schlessinger · Cell Open access Jun 2010 8,012
All 97 most cited papers, with filters and sorting

Where is HER2/EGFR in Cancer Research research done?

The largest centres of HER2/EGFR in Cancer Research research in 2022-now are Beijing (China), Shanghai (China), New York (United States) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Kashiwa.

Largest cities, 2022-now

  1. 1 BeijingChina 231 works
  2. 2 ShanghaiChina 182 works
  3. 3 New YorkUnited States 145 works
  4. 4 SeoulSouth Korea 130 works
  5. 5 GuangzhouChina 121 works
  6. 6 TokyoJapan 116 works
  7. 7 HoustonUnited States 107 works
  8. 8 BostonUnited States 101 works
  9. 9 HangzhouChina 88 works
  10. 10 LondonUnited Kingdom 83 works

Where it is the local speciality

  1. KashiwaJP · 25.2 works38×
← less than its size predicts1×more →

Location quotient: how much more of its research is in HER2/EGFR in Cancer Research than the world average.

See HER2/EGFR in Cancer Research on the map

Where is the best place to study HER2/EGFR in Cancer Research?

Among universities, judged by research, Harvard University, University of Milan and University of California, San Francisco score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 16.78%fractional works in this field (log) →share of work in the world top 10% →University of MilanHarvard UniversityCornell UniversityUniversity of Califo…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 91.421.4%5.2×110 +42.4%
2University of MilanItaly 69.427.7%4.0×17 +39.9%
3University of California, San FranciscoUnited States 67.215.3%6.1×29 +21.3%
4Cornell UniversityUnited States 65.819.5%2.9×25 +25.3%
5Sun Yat-sen UniversityChina 65.714.3%5.6×77 +113.8%
6Universitat Autònoma de BarcelonaSpain 64.819.7%3.4×14 +39.0%
7Yale UniversityUnited States 63.613.2%5.2×37 +74.5%
8Sichuan UniversityChina 57.816.7%2.8×42 +158.7%
9Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 56.49.8%8.5×60 +117.4%
10University of California, Los AngelesUnited States 55.510.2%3.0×23 +36.9%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in HER2/EGFR in Cancer Research, country by country

Is HER2/EGFR in Cancer Research research growing?

Output in 2022-2025 was 29% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are HER2/EGFR in Cancer Research.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is HER2/EGFR in Cancer Research as a percentage of every work published that year, 0.029% in 2024.

still counting0.020%0.040%HER2/EGFR in Cancer Research0.034% in 202519801990200020102020

Fractional works of HER2/EGFR in Cancer Research over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%HER2/EGFR in Cancer Research10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about HER2/EGFR in Cancer Research. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.